The Pharmaceutical Industry Within the U.S.: The Method U.S. Pharmaceutical Corporations Leverage to Extend Patents, How These Small Changes Toward Patents Work, the Only Restriction of This Strategy, the 3 Largest Producers of Insulin Within the U.S. and the Reason Insulin Cannot Be Manufactured More Cost Effectively Within the U.S., the Persons Who Discovered Insulin and the Economic Value the Patent of Insulin Was Sold for, the Organization Which Licensed the Patent of Insulin to U.S. Pharmaceutical Corporation Eli Lilly, Danish Pharmaceutical Corporation Novo Nordisk, and French Pharmaceutical Corporation Sanofi, the Majority of Pharmaceutical Patents Being Filed for Pre-Existing Medications During the 21st Century, the Disbenefit to the U.S. Public of the Economic Cost of Insulin Remaining Constant Between the 3 Largest U.S. Manufacturers of Insulin, the Rationale Pharmaceutical Corporations Provide to Justify the Increasing Cost of Insulin, the Organization the Pharmaceutical Industry Attributes Fault Toward for the High Economic Cost of Medication, the 3 Largest Pharmacy Benefit Manager Organizations Within the U.S., the Reason These Organizations Possess a Conflict of Interest, the Organization Authorized to Break U.S. Patents During a State of Emergency, the Reason Pharmaceutical Manufacturers Have Decreased the Economic Cost of Medication in the Past, and the Total Economic Cost of the Pharmaceutical Industry Lobbying the U.S. Congress in 2018